Page 26 - Read Online

Page 8 of 8 Lee et al. Vessel Plus 2021;5:8 I http://dx.doi.org/10.20517/2574-1209.2020.72

16. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and
restorative drug development. Stroke 1999;30:2752-8.
17. Feuerstein GZ, Zaleska MM, Krams M, et al. Missing steps in the STAIR case: a Translational Medicine perspective on the development
of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab 2008;28:217-9.
18. Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 2007;61:396-402.
19. Fisher M, Feuerstein G, Howells DW, et al; STAIR Group. Update of the stroke therapy academic industry roundtable preclinical
recommendations. Stroke 2009;40:2244-50.
20. Visscher PM, Wray NR, Zhang Q, et al. 10 years of GWAS discovery: biology, function, and translation. Am J Hum Genet 2017;101:5-22.
21. DeAngelis MM, Owen LA, Morrison MA, et al. Genetics of age-related macular degeneration (AMD). Hum Mol Genet 2017;26:R45-50.
22. Furey TS, Sethupathy P, Sheikh SZ. Redefining the IBDs using genome-scale molecular phenotyping. Nat Rev Gastroenterol Hepatol
2019;16:296-311.
23. Zheng H, Zeng Z, Wen H, et al. Application of genome-wide association studies in coronary artery disease. Curr Pharm Des
2019;25:4274-86.
24. Rohde K, Keller M, la Cour Poulsen L, Blüher M, Kovacs P, Böttcher Y. Genetics and epigenetics in obesity. Metabolism 2019;92:37-50.
25. Horwitz T, Lam K, Chen Y, Xia Y, Liu C. A decade in psychiatric GWAS research. Mol Psychiatry 2019;24:378-89.
26. Andrews SJ, Fulton-howard B, Goate A. Interpretation of risk loci from genome-wide association studies of Alzheimer’s disease. Lancet
Neurology 2020;19:326-35.
27. Chen Q, Zhou XJ, Sun F. Finding genetic overlaps among diseases based on ranked gene lists. J Comput Biol 2015;22:111-23.
28. Jhamb D, Magid-Slav M, Hurle MR, Agarwal P. Pathway analysis of GWAS loci identifies novel drug targets and repurposing
opportunities. Drug Discov Today 2019;24:1232-6.
29. Parvathaneni V, Kulkarni NS, Muth A, Gupta V. Drug repurposing: a promising tool to accelerate the drug discovery process. Drug
Discov Today 2019;24:2076-85.
30. Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat
Rev Drug Discov 2014;13:419-31.
31. Nelson MR, Tipney H, Painter JL, et al. The support of human genetic evidence for approved drug indications. Nat Genet 2015;47:856-60.
32. Heitsch L, Ibanez L, Carrera C, et al. Early neurological change after ischemic stroke is associated with 90-day outcome. Stroke 52:132-41.
33. Zaitlen N, Paşaniuc B, Gur T, Ziv E, Halperin E. Leveraging genetic variability across populations for the identification of causal variants.
Am J Hum Genet 2010;86:23-33.
34. Cooper RS, Tayo B, Zhu X. Genome-wide association studies: implications for multiethnic samples. Hum Mol Genet 2008;17:R151-5.
35. Morris AP. Transethnic meta-analysis of genomewide association studies. Genet Epidemiol 2011;35:809-22.
36. Ibanez L, Heitsch L, Carrera C, et al. Multi-ancestry genetic study in 5,876 patients identifies an association between excitotoxic genes
and early outcomes after acute ischemic stroke. medRxiv 2020:2020.
37. Del-Aguila JL, Li Z, Dube U, et al. A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimers
Res Ther 2019;11:71.
38. Ge P, Dawson VL, Dawson TM. PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s
disease. Mol Neurodegener 2020;15:20.
39. Zhong S, Khalil RA. A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in
vascular biology and disease. Biochem Pharmacol 2019;164:188-204.
40. Hivert B, Marien L, Agbam KN, Faivre-Sarrailh C. ADAM22 and ADAM23 modulate the targeting of the Kv1 channel-associated
protein LGI1 to the axon initial segment. J Cell Sci 2019;132:jcs219774.
41. Lancaster E, Burnor E, Zhang J, Lancaster E. ADAM23 is a negative regulator of K v 1.1/K v 1.4 potassium currents. Neurosci Lett
2019;704:159-63.
42. van Sonderen A, Petit-Pedrol M, Dalmau J, Titulaer MJ. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in
encephalitis. Nat Rev Neurol 2017;13:290-301.
43. Petit-Pedrol M, Sell J, Planagumà J, et al. LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and
memory. Brain 2018;141:3144-59.
44. Fukata Y, Adesnik H, Iwanaga T, Bredt DS, Nicoll RA, Fukata M. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate
synaptic transmission. Science 2006;313:1792-5.
45. Koskinen LL, Seppälä EH, Weissl J, et al. ADAM23 is a common risk gene for canine idiopathic epilepsy. BMC Genet 2017;18:8.
46. Lovero KL, Fukata Y, Granger AJ, Fukata M, Nicoll RA. The LGI1-ADAM22 protein complex directs synapse maturation through
regulation of PSD-95 function. Proc Natl Acad Sci U S A 2015;112:E4129-37.
47. Palmer CL, Cotton L, Henley JM. The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors. Pharmacol Rev 2005;57:253-77.
48. Chamorro Á, Dirnagl U, Urra X, Planas AM. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress,
and inflammation. The Lancet Neurology 2016;15:869-81.
49. Neuhaus AA, Couch Y, Hadley G, Buchan AM. Neuroprotection in stroke: the importance of collaboration and reproducibility. Brain
2017;140:2079-92.
50. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol 2017;18:83.